In a rerun of last summer’s political interference in pharmaceutical pricing spearheaded by both Bernie Sanders and Hillary Clinton, which initially focused on Martin Shrekli’s price hike of the Turing Pharmaceuticals Daraprim drug, then shifted to Allergan (and everyone knows what happened after), over the past few days much of the media’s attention has focused on the ongoing cost increases of Mylan’s Epipen.